Vol 7, Supplement 3 (September 2018): Translational Lung Cancer Research1


Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC
Rafael Rosell, Niki Karachaliou, Carles Codony-Servat, Masaoki Ito
Osimertinib in first line setting: preventive or delayed T790M occurrence?
Hao Sun, Yilong Wu
COX-2 inhibitors in NSCLC: never-ending story or misplaced?
Alex Martinez-Marti, Alejandro Navarro, Enriqueta Felip
Is more the better?—cetuximab in non-small cell lung cancer patients
Teresa Moran
Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?
Niki Karachaliou, Manuel Fernandez-Bruno, Rafael Rosell
A new era of treating advanced lung cancer is upon us
Glen J. Weiss
Thymectomy as an oncologic and immunologic treatment
Masatsugu Hamaji
Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?
Monica S. Chatwal, Tawee Tanvetyanon
Immunotherapy efficacy and gender: discovery in precision medicine
Bryan C. Ulrich, Nicolas Guibert
Lung cancer and chronic obstructive pulmonary disease: understanding the complexity of carcinogenesis
Cecilia Mouronte-Roibás, Alberto Ruano-Raviña, Alberto Fernández-Villar
Identification of a novel therapeutic target in driver-negative nonsmall cell lung cancer
Motonobu Saito, Koji Kono, Takashi Kohno
Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy
Umberto Malapelle, Antonino Iaccarino, Antonio Rossi
Histology versus cytology: PD-L1 testing in non-small cell lung cancer
Nagio Takigawa, Nobuaki Ochi, Hiromichi Yamane
Development of biomarkers for real precision medicine
Masahiro Shibata, Mohammad Obaidul Hoque
Intraoperative molecular imaging—a bright navigator for thoracic surgeons in the era of limited resection
Kenichi Suda
The impact of patients’ preferences on the decision of low-dose computed tomography lung cancer screening
Fu-Zong Wu, Pei-Lun Kuo, Carol C. Wu, Ming-Ting Wu
LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC
Rachael Chang Lee, Bibhusal Thapa, Thomas John
Targeting IL22: a potential therapeutic approach for Kras mutant lung cancer?
Frank D. Weinberg, Nithya Ramnath
Studying the immune landscape in lung cancer models: choosing the right experimental tools
Clare E. Weeden, Casey Ah-Cann, Marie-Liesse Asselin-Labat
Subtype variation and actionability of telomere length abnormality in lung cancer
Felicia Goh, Ian A. Yang, Rayleen V. Bowman, Kwun M. Fong
Hunting for transcription factors: STAT3 decoy in non-small cell lung cancer
Joseph Carmicheal, Sukhwinder Kaur, Surinder K. Batra, Apar Kishor Ganti
Thymic tumors with parathymic syndromes: good or bad?
Andrea Dell’Amore, Alessio Campisi
Finding paths with the greatest chance of success: enabling and focusing lung cancer screening and cessation in resourceconstrained areas
Wiley D. Jenkins, David Gilbert, Li-Shiun Chen, Leslie R. Carnahan
Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach
Sharon R. Pine, Bríd M. Ryan
Tobacco cessation in lung cancer screening—do we have the evidence?
Emily Stone, Henry Marshall

Brief Report

Multidisciplinary quality improvement initiative to standardize reporting of lung cancer screening
Laura Cubillos, Alison T. Brenner, Katherine Birchard, Louise M. Henderson, Paul L. Molina, Michael Pignone, Shana Ratner, M. Patricia Rivera, Laura Jones, Daniel S. Reuland


1. The supplement was published without any sponsorship or funding.

2. The series “Controversies on Lung Cancer: Pros and Cons” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Suresh Senan and Helmut H. Popper served as the unpaid Guest Editors for the series.